Will Bayer’s Finerenone beat new breakthrough therapies in Diabetic Kidney Disease ?
Diabetes is considered to be one of the top reasons for Kidney failure. Controlling diabetes is absolutely the first step towards slowing down the progression of diabetic nephropathy. Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers have been the primary level of treatment therapies for diabetic nephropathy. In the wake of already constrained treatment options available, potential benefits of mineralocorticoid receptor antagonist (MRA) in combination to angiotensin-converting enzyme inhibitors (ACEI) and/or angiotensin receptor blockers (ARB) is coming into the picture. MRAs are also one of the Physician’s favored treatment MOA as per a report published by DRG. One of the promising mineralocorticoid receptor antagonist (MRA) candidate in Phase III is Bayer’s Finerenone. Other companies, including Daiichi-Sankyo, Eli Lilly, and Pfizer, are also developing nonsteroidal MRAs for the treatment of chronic kidney diseases thus rapidly increasing the hope in Diabetic Nephropathy space, although increasing the competition for players in DN space.
